GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Medlive Technology Co Ltd (HKSE:02192) » Definitions » YoY EBITDA Growth

Medlive Technology Co (HKSE:02192) YoY EBITDA Growth : 43.83% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Medlive Technology Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Medlive Technology Co's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 43.83%.

Medlive Technology Co's EBITDA per Share for the six months ended in Dec. 2023 was HK$0.23.


Medlive Technology Co YoY EBITDA Growth Historical Data

The historical data trend for Medlive Technology Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlive Technology Co YoY EBITDA Growth Chart

Medlive Technology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial 100.00 179.41 -22.11 47.97 78.54

Medlive Technology Co Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only -43.36 -11.59 153.13 160.66 43.83

Medlive Technology Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Medlive Technology Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(0.391-0.219)/ | 0.219 |
=78.54 %

Medlive Technology Co's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(0.233-0.162)/ | 0.162 |
=43.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medlive Technology Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Medlive Technology Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Medlive Technology Co (HKSE:02192) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Baijialou Chaoyang North Road, E1 Red Manor International Bonded Innovation Park, Chaoyang District, Beijing, CHN
Medlive is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms to specifically target physicians through different promotional channels. The company uses in-house and third-party content teams to produce advertising for its clients by profiling the user preferences of the physicians on the platform who drive procurement and prescription decisions. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and SaaS solution that help with medical conferences and clinical research. M3, Japan's leading digital healthcare marketing company owns 38.8% of Medlive through a joint venture.
Executives
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
M3, Inc. 2101 Beneficial owner
Sony Group Corporation 2201 Interest of corporation controlled by you
Tian Liping
Zhang Xiaofeng 2101 Beneficial owner
Liu Lingdi 2101 Beneficial owner
Tian Lixin 2101 Beneficial owner
Brown Brothers Harriman & Co. 2502 Approved lending agent
Fidelity Funds 2101 Beneficial owner
Tiantian Co., Limited

Medlive Technology Co (HKSE:02192) Headlines

No Headlines